Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489570 | 0.93 | BCL2 (0.46) | BCL2MCL1MRGPRX4PLA2G4BPLA2G2A | |
| SCHEMBL6502208 | 0.88 | MCL1 (0.44) | BCL2MCL1MRGPRX4 | |
| SCHEMBL6496934 | 0.87 | MCL1 (0.54) | BCL2MCL1PLA2G2A | |
| SCHEMBL7194322 | 0.87 | BCL2 (0.48) | BCL2MCL1MRGPRX4PLA2G2A | |
| SCHEMBL6497730 | 0.87 | PPARG (0.44) | MCL1PLA2G4BPLA2G2ATP53 | |
| SCHEMBL6497678 | 0.86 | PTPN11 (0.46) | PLA2G4B | |
| SCHEMBL6488344 | 0.85 | MCL1 (0.47) | MCL1PLA2G4BPLA2G2A | |
| SCHEMBL6489346 | 0.84 | MRGPRX4 (0.46) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL6501700 | 0.84 | MCL1 (0.40) | BCL2MCL1 | |
| SCHEMBL6500130 | 0.83 | DCTPP1 (0.47) | BCL2MCL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | BCL2 774/4885MCL1 806/4885MRGPRX4 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.